EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients

ROCKLAND, Mass., May 28, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data from its multiple sclerosis (MS) portfolio at the Consortium of Multiple Sclerosis Centers (CMSC) 2019 Annual Meeting, taking place May 28 - June 1, 2019 in Seattle, WA. The company will present a total of 20 abstracts (18 posters and two oral presentations), including new data on MAVENCLAD(®) (cladribine) tablets.

"We are dedicated to the continuation of research into our MS portfolio, and are excited to have a strong scientific presence at the CMSC Annual Meeting," said John Walsh, M.D., Vice President, Neurology and Immunology, U.S. Medical Affairs and Interim Head, North America Medical Affairs at EMD Serono. "Presenting these data reaffirms our commitment to fully understand the science of MS and ensure patient needs are at the forefront of MS care."

Meeting attendees can learn more about EMD Serono and its support of the MS community by visiting and participating in interactive activities at the congress, including "I'm Balancing MS," at booth #101. Individuals can work with their colleagues to create an original art piece depicting the neuroimmunology of MS. For each participant, EMD Serono will make a donation to the Foundation of CMSC's Workforce of the Future, which supports initiatives for young professionals who care for people with MS including The International Organization of Multiple Sclerosis Nurses (IOMSN).

"EMD Serono has spearheaded this effort over the past two decades and their support has been instrumental in our progress," said June Halper, CEO of CMSC. "IOMSN is dedicated to sustain nursing care in MS throughout the world. Its growth and positive impact on MS care is due, in no small measure, to scholarship funding and support of its educational activities by its supporters."

In addition, EMD Serono will honor World MS Day at CMSC on May 30 by showcasing multiple pieces of artwork from the MS On My Mind (MSOMM) initiative, including a final mural created at National MS Society Walk MS events across the country. The mural incorporates personalized messages from Walk MS attendees and will come together for the first time at CMSC. CMSC attendees can visit booth #236 to meet MSOMM creative director, Lydia Emily Archibald, and see her artwork inspired by submissions from those impacted by MS.

Below is a selection of abstracts that have been accepted for presentation at CMSC 2019:



       
              MAVENCLAD(R) (cladribine) tablets data

    ---

                   Title                
            
              Lead Author 
     
              Poster                       Presentation/ Session

    ---                                                                                                                             ---

        Severity and frequency
         of relapses in
         patients with
         relapsing-remitting
         MS treated with
         Cladribine Tablets in
         CLARITY and placebo
         in CLARITY Extension           
            Schippling S           
     DXT55               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        Efficacy of Cladribine
         Tablets 3.5mg/kg in
         patients with
         relapsing multiple
         sclerosis aged above
         and below 45 years;
         CLARITY and CLARITY
         Extension                      
            Giovannoni G           
     DXT53               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        Rationale and
         feasibility of a
         phase IV study
         (CLASSIC MS)
         assessing long-term
         efficacy outcomes for
         patients with
         multiple sclerosis
         treated with
         Cladribine Tablets in
         the phase III trials           
            Boyko A                
     DXT35               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        The effects of
         cladribine tablets on
         reduction in MRI
         lesions are
         consistent across
         subgroups in the
         ORACLE-MS study                
            Leist T                
     Oral Presentation   
            Friday May 31

                                                                                            
            3:20 PM - 3:40 PM PT

                                                                                                     Washington State Convention
                                                                                            Center 611-612

    ---                                                                                                                             ---

        Relapse outcomes in
         CLARITY EXT patients
         treated with
         cladribine tablets or
         placebo were
         comparable regardless
         of the between-trial
         bridging intervals             
            Rammohan K             
     DXT56               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        Network meta-analysis
         of cladribine tablets
         versus alternative
         disease-modifying
         treatments for
         relapsing-remitting
         multiple sclerosis:
         tolerability and
         quality-of-life
         outcomes                       
            Singer B               
     DXT57               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        CLARITY Extension:
         Long-term efficacy
         of cladribine tablets
         in patients with high
         disease activity at
         baseline following
         switch to placebo              
            Vermersch P            
     DXT31               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        Updated safety
         analysis of
         cladribine tablets in
         the treatment of
         patients with
         multiple sclerosis             
            Cook S                 
     DXT58               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        Durability of NEDA-3
         status in patients
         with relapsing
         multiple sclerosis
         receiving cladribine
         tablets: CLARITY
         Extension                      
            Giovannoni G           
     DXT01               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---


       
              Evobrutinib data

    ---

        Efficacy and Safety of
         the Bruton's Tyrosine
         Kinase Inhibitor
         Evobrutinib (M2951)
         in Patients With
         Relapsing MS Over 48
         Weeks: a Phase II
         Study                          
            Montalban X            
     Oral Presentation   
            Friday May 31

                                                                                            
            3:40 PM - 4:00 PM PT

                                                                                                     Washington State Convention
                                                                                            Center 611-612

    ---                                                                                                                             ---

        Inhibition of Bruton's
         tyrosine kinase
         prevents inflammatory
         macrophage
         differentiation: a
         potential role in
         multiple sclerosis             
            Alankus YB             
     NDM05               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---


       
              Rebif(R) (interferon beta-1a) data

    ---

        Real-world infection
         rates and lymphocyte
         counts in patients
         >=50 years with
         relapsing-remitting
         MS treated with
         subcutaneous
         interferon beta-1a
         or dimethyl fumarate           
            Hayward B              
     DXT68               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        Cumulative data from
         the European
         Interferon Beta
         Pregnancy Registry             
            Hellwig K              
     DXT66               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        Dynamics of
         pseudoatrophy in
         relapsing-remitting
         MS patients treated
         with interferon beta-
         1a as assessed by
         monthly brain MRI              
            Battaglini M           
     DXT61               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        MAGNIMS score-assessed
         disease activity
         predicts long-term
         activity-free status
         and disability
         progression in
         subcutaneous
         interferon beta-
         1a-treated patients            
            Sormani MP             
     DXT02               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---


       
              HEOR data

    ---

        Comorbidity and
         concomitant
         medication use among
         patients with
         multiple sclerosis
         newly initiating
         disease-modifying
         drugs                          
            Nicholas J             
     DXT33               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        Gaps in treatment and
         treatment
         discontinuation among
         patients with
         multiple sclerosis
         newly initiating
         once- or twice-
         daily oral disease-
         modifying drugs                
            Nicholas J             
     DXT34               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        Clinical and economic
         burden of non-
         adherence to oral
         disease-modifying
         drugs in patients
         with multiple
         sclerosis: a cost-
         consequence model              
            Nicholas J             
     DXT38               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

        Relapses, healthcare
         resource use, and
         costs among patients
         with multiple
         sclerosis taking
         maintenance (once-or
         twice-daily) oral
         disease-modifying
         drugs and
         experiencing lapses
         in therapy                     
            Nicholas J             
     DXT32               
            Thursday May 30

                                                                                            
            6:45 PM - 8:15 PM PT

                                                                                            
            Poster Session

    ---                                                                                                                             ---

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About MAVENCLAD(®)
MAVENCLAD, approved by the U.S. Food and Drug Administration (FDA) on March 29, 2019, is the first and only short-course oral therapy for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of multiple sclerosis (MS), and MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS). The approved dose of MAVENCLAD is 3.5 mg per kg body weight over two years, administered as one treatment course of 1.75 mg per kg per year, each consisting of two treatment weeks. The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully elucidated but is thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes.

Because cladribine is cytotoxic, special handling and disposal instructions should be followed.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: MALIGNANCIES and RISK OF TERATOGENICITY

    --  Treatment with MAVENCLAD may increase the risk of malignancy. MAVENCLAD
        is contraindicated in patients with current malignancy; evaluate the
        benefits and risks of the use of MAVENCLAD on an individual patient
        basis for patients with prior or increased risk of malignancy. Follow
        standard cancer screening guidelines in patients treated with MAVENCLAD.
    --  MAVENCLAD is contraindicated for use in pregnant women and in women and
        men of reproductive potential who do not plan to use effective
        contraception because of the potential for fetal harm.

CONTRAINDICATIONS

    --  Current malignancy.
    --  Pregnancy, and women and men of reproductive potential who do not plan
        to use effective contraception during MAVENCLAD dosing and for 6 m after
        the last dose in each treatment course.
    --  Human immunodeficiency virus (HIV).
    --  Active chronic infections (e.g., hepatitis or tuberculosis).
    --  History of hypersensitivity to cladribine.
    --  Breastfeeding while taking MAVENCLAD and for 10 days after the last
        dose.

DOSING CONSIDERATIONS: After the completion of 2 treatment courses, do not administer additional MAVENCLAD during the next 2 years. The risk of malignancy with reinitiating MAVENCLAD more than 2 years after completion of 2 treatment courses has not been studied.

ADDITIONAL WARNINGS AND PRECAUTIONS

    --  Lymphopenia: In clinical studies, 87% of MAVENCLAD-treated patients
        experienced lymphopenia. Concomitant use of MAVENCLAD with hematotoxic
        drugs may increase the risk of adverse reactions because of the additive
        hematological effects. Monitor lymphocyte counts before and during
        treatment, periodically thereafter, and when clinically indicated.
    --  Infections: Infections occurred in 49% of MAVENCLAD-treated patients
        compared to 44% of patients treated with placebo in clinical studies.
        The most frequent serious infections included herpes zoster and
        pyelonephritis. Single fatal cases of tuberculosis and fulminant
        hepatitis B were reported in the clinical program. Administer
        live-attenuated or live vaccines at least 4 to 6 weeks prior to starting
        MAVENCLAD. Screen patients for latent infections; consider delaying
        treatment until infection is fully controlled. Vaccinate patients
        antibody-negative to varicella zoster virus prior to treatment. Monitor
        for infections.
    --  Hematologic Toxicity: Mild to moderate decreases in neutrophil counts,
        hemoglobin levels, and platelet counts were observed. Severe decreases
        in neutrophil counts were observed in 3.6% of MAVENCLAD-treated
        patients, compared to 2.8% of placebo patients. Obtain complete blood
        count (CBC) with differential including lymphocyte count before and
        during treatment, periodically thereafter, and when clinically
        indicated.
    --  Risk of Graft-versus-Host Disease With Blood Transfusions: Irradiation
        of cellular blood components is recommended.
    --  Liver Injury: Obtain liver function tests prior to treatment.
        Discontinue MAVENCLAD if significant injury is suspected.
    --  Hypersensitivity: In clinical studies, 11% of MAVENCLAD-treated patients
        had hypersensitivity reactions, compared to 7% of placebo patients.
        Serious hypersensitivity reactions occurred in 0.5% of MAVENCLAD-treated
        patients, compared to 0.1% of placebo patients. If a hypersensitivity
        reaction is suspected, discontinue treatment. Do not use MAVENCLAD in
        patients with a history of hypersensitivity to cladribine.

Adverse Reactions: The most common adverse reactions with an incidence of >20% for MAVENCLAD are upper respiratory tract infection, headache, and lymphopenia.

Drug Interactions/Concomitant Medication: Concomitant use of MAVENCLAD with immunosuppressive or myelosuppressive drugs and some immunomodulatory drugs (e.g., interferon beta) is not recommended and may increase the risk of adverse reactions. Avoid concomitant use of certain antiviral and antiretroviral drugs. Avoid concomitant use of BCRP or ENT/CNT inhibitors as they may alter bioavailability of MAVENCLAD.

Please see the full Prescribing Information, including boxed WARNING for additional information.

About Evobrutinib
Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). It is an oral, highly specific inhibitor of Bruton's tyrosine kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. BTK inhibition is thought to suppress autoantibody-producing cells, which preclinical research suggests may be therapeutically useful in certain autoimmune diseases. Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.

About Rebif(®) (interferon beta-1a)
Rebif (interferon beta-1a) is used to treat relapsing forms of MS to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS. The efficacy and safety of Rebif in controlled clinical trials beyond 2-years has not been established.

IMPORTANT SAFETY INFORMATION
Rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation.

Rebif should be used with caution in patients with depression, a condition that is common in people with multiple sclerosis. Depression, suicidal ideation, and suicide attempts have been reported to occur with increased frequency in patients receiving interferon compounds, including Rebif.

Severe liver injury, including some cases of hepatic failure requiring liver transplantation, has been reported rarely in patients taking Rebif. The potential for liver injury should be considered when used in combination with other products associated with liver injury. Monitor liver function tests and patients for signs and symptoms of hepatic injury. Consider discontinuing Rebif if hepatic injury occurs.

Anaphylaxis and other allergic reactions (some severe) have been reported as a rare complication of Rebif. Discontinue Rebif if anaphylaxis occurs.

In controlled clinical trials, injection site reactions occurred more frequently in Rebif-treated patients than in placebo-treated and Avonex-treated patients. Injection site reactions including injection site pain, erythema, edema, cellulitis, abscess, and necrosis have been reported in the postmarketing setting. Do not administer Rebif into affected area until fully healed; if multiple lesions occur, discontinue Rebif until skin lesions are healed.

Decreased peripheral blood counts in all cell lines, including pancytopenia, have been reported in Rebif-treated patients. In controlled clinical trials, leukopenia occurred at a higher frequency in Rebif-treated patients than in placebo and Avonex-treated patients. Thrombocytopenia and anemia occurred more frequently in 44 mcg Rebif-treated patients than in placebo-treated patients. Patients should be monitored for symptoms or signs of decreased blood counts. Monitoring of complete blood and differential white blood cell counts is also recommended.

Cases of thrombotic microangiopathy (TMA), some fatal, have been reported with interferon beta products, including Rebif, up to several weeks or years after starting therapy. Discontinue Rebif if clinical symptoms and laboratory findings consistent with TMA occur, and manage as clinically indicated.

Caution should be exercised when administering Rebif to patients with pre-existing seizure disorders. Seizures have been temporally associated with the use of beta interferons, including Rebif, in clinical trials and in postmarketing reports.

The most common side effects with Rebif are injection-site disorders, headaches, influenza-like symptoms, abdominal pain, depression, elevated liver enzymes, and hematologic abnormalities.

There are no adequate and well-controlled studies in pregnant women. Rebif should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Rebif full prescribing information is available at http://www.emdserono.com/ms.country.us/en/images/Rebif_PI_tcm115_140051.pdf?Version=

About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that more than 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

EMD Serono, Inc. and Multiple Sclerosis
For more than 20 years, EMD Serono has been relentlessly focused on understanding the journey people living with MS face in order to create a meaningful, positive experience for them and the broader MS community. However, there is still much that is unknown about this complex and unpredictable disease. EMD Serono is digging deeper to advance the science.

About EMD Serono, Inc.
EMD Serono - the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada - is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and MS. Today, the business has approximately 1,300 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts. www.emdserono.com

Contact
alice.mcgrail@emdserono.com
Phone: +1 781 738 8791

View original content to download multimedia:http://www.prnewswire.com/news-releases/emd-serono-to-present-data-at-cmsc-annual-meeting-showcasing-breadth-of-ms-portfolio-and-commitment-to-understanding-how-ms-impacts-patients-300857558.html

SOURCE EMD Serono